Ropes & Gray advised Atavistik Bio in a strategic research collaboration with Roche to discover and develop novel small molecule therapeutics against multiple targets for cardiovascular, renal, and metabolic (CVRM) diseases in a deal worth up to $2 billion that was announced on September 24.
The collaboration will leverage Atavistik Bio’s proprietary AMPS drug discovery platform and experience in allosteric drug discovery to identify hidden pockets on disease-causing proteins, potentially allowing drugs to be developed against CVRM targets that have been challenging to modulate.
Under the agreement, Atavistik will receive an upfront payment of $70 million and is eligible to receive additional milestone payments up to $1.9 billion, plus tiered royalties on future net sales of approved treatments. Atavistik will lead early discovery and research, while Roche will be responsible for further preclinical and clinical development, regulatory filings and commercialization.
The Ropes & Gray team included life sciences licensing partner Hannah England and associate Ian Nilsen.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.